COST-UTILITY ANALYSIS AND EFFICIENCY FRONTIER APPROACH OF TAFASITAMAB IN BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Fahham, L. [1 ]
Dias, L. [2 ]
Amaral, L. Murta [2 ]
Mazzuco, C. [3 ]
Araujo, G. [3 ]
机构：
[1] ORIGIN Hlth, Sao Paulo, Brazil
[2] ORIGIN Hlth, Rio De Janeiro, RJ, Brazil
[3] Knight Therapeut, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE442
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Cost-utility analysis of methadone maintenance treatment: A methodological approach
    Vanagas, G
    Padaiga, Z
    Bagdonas, E
    SUBSTANCE USE & MISUSE, 2006, 41 (01) : 87 - 101
  • [42] Cost-Utility of Venoarterial Extracorporeal Membrane Oxygenation in Refractory Cardiogenic Shock: A Brazilian Perspective Study
    Decker, Sergio Renato da Rosa
    Wainstein, Rodrigo Vugman
    Scolari, Fernando Luis
    Rosa, Priscila Raupp da
    Schneider, Daniel
    Fogazzi, Debora Vacaro
    Trott, Geraldine
    Wolf, Jonas
    Teixeira, Cassiano
    Rover, Marciane Maria
    Nasi, Luiz Antonio
    Rohde, Luis Eduardo
    Polanczyk, Carisi Anne
    Rosa, Regis Goulart
    Bertoldi, Eduardo Gehling
    ARQUIVOS BRASILEIROS DE CARDIOLOGIA, 2024, 121 (08)
  • [43] BUDGET IMPACT ANALYSIS OF TOFACITINIB FOR RHEUMATOID ARTHRITIS FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM
    Ferreira, C. N.
    Rufino, C. S.
    Santana, C. F.
    Dulcine, M.
    VALUE IN HEALTH, 2015, 18 (07) : A638 - A638
  • [44] COST-EFFECTIVENESS OF SACUBITRIL/VALSARTAN IN THE TREATMENT OF HEART FAILURE UNDER THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Libanore, A.
    Lopes, N.
    Lacey, M. J.
    Tozato, C.
    VALUE IN HEALTH, 2018, 21 : S107 - S107
  • [45] SURGICAL SITES INFECTION: A MICRO-COSTING APPROACH FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Campos, D.
    Perez, V
    Martins, L.
    Pepe, C.
    Arinelli, R.
    VALUE IN HEALTH, 2022, 25 (07) : S398 - S398
  • [46] COST-CONSEQUENCE ANALYSIS OF SUBCUTANEOUS ABATACEPT VERSUS ADALIMUMAB IN RHEUMATOID ARTHRITIS BY ACPA STATUS - BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Marinheiro, P.
    Faustino, P.
    Watanabe, S.
    Lima, P.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2020, 26 : 136 - 136
  • [47] COST-UTILITY ANALYSIS OF THE CYBERKNIFE SYSTEM FOR METASTATIC SPINAL TUMORS
    Papatheofanis, Frank J.
    Williams, Erin
    Chang, Steven D.
    NEUROSURGERY, 2009, 64 (02) : A73 - A83
  • [48] COST PER RESPONDER ANALYSIS OF BIOLOGIC TREATMENTS FOR ULCERATIVE COLITIS IN BIOLOGIC NAIVE PATIENTS FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Souza, P. V. S.
    Baida, R.
    Gomes, T. N. F.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [49] COST BY OUTCOMES ANALYSIS OF BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR ACUTE LYMPHOBLASTIC LEUKEMIA FROM THE BRAZILIAN PRIVATE HEALTHCARE PERSPECTIVE
    Tanaka, S.
    Lunk, I
    Arancibia, A.
    Aratangy, G.
    VALUE IN HEALTH, 2020, 23 : S52 - S52
  • [50] Lacosamide as a first-line treatment option in focal epilepsy: a cost-utility analysis for the Greek healthcare system
    Geitona, Mary
    Stamuli, Eugena
    Giannakodimos, Stylianos
    Kimiskidis, Vasileios K.
    Kountouris, Vasileios
    Charokopou, Mata
    Christou, Petros
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 359 - 364
12345